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A B S T R A C T
During the early phase of an acute myocardial infarction (MI), current consensus is 
that reperfusion of the infarct-related artery (IRA) should be implemented as soon 
as possible, more effectively accomplished via percutaneous coronary intervention 
(PCI). The clinical approach to the occluded IRA late after MI remains controversial, 
but current practice shows a strong trend in favour of PCI, which is based on the late 
open artery hypothesis. However, late PCI on IRAs also has the potential for harm 
from procedure-related complications. An attempt is made herein to critically over-
view the current data on this important topic, mainly based on recent meta-analyses 
with somewhat diverging results, indicating that clinical judgment and an individual-
ized approach still remains a valid guide.
I N T R O D U C T I O N
During the early phase of an acute myocardial infarction (MI), current consensus 
is that reperfusion of the infarct-related artery (IRA) should be implemented as soon 
as possible. According to the current ACC/AHA/SCAI and ESC guidelines primary 
percutaneous coronary intervention (PCI) is the treatment of choice when delivered 
rapidly (no longer than 90 minutes from patient’s first medical contact), by experienced 
teams in high-volume centers, specifically when the time from the onset of symptoms 
is shorter than 12 hours.1, 2 In this early phase the main goal is myocardial salvage, 
which is critically time-dependent. Prompt restoration of blood flow reduces infarct 
size, preserves global left ventricular function, and thus improves patient survival.
Unfortunately, the number of patients treated within 12 hours of the onset of 
symptoms is still disappointing, since 8.5% to 40% of patients present beyond 12 
hours.3 The clinical approach to the occluded IRA late after MI remains variable and 
controversial, but current practice shows a strong trend in favour of PCI, which is based 
on the late open artery hypothesis.4, 5 According to this theory late patency of an IRA 
is associated with reduction in adverse post-infarction remodelling, increased electri-
cal stability, and provision of collateral vessels to other coronary beds for protection 
against future events.6 It was initially conceived during the fibrinolytic era when several 
studies suggested that the effects of IRA reperfusion on left ventricular function and 
survival might, to some extent, be independent of one another.7, 8 Further support was 
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provided by nonrandomized, retrospective studies of patients 
with a first MI, where long-term survival was found to be 
substantially better among those with anterograde flow in the 
infarct-related artery than among those whose infarct-related 
artery was persistently occluded.9, 10 Other studies showed that 
patients with a persistently occluded IRA after MI were more 
likely than those with a patent artery to have late potentials on 
signal-averaged electrocardiography and inducible ventricular 
tachyarrhythmias during invasive programmed electrical 
stimulation.11, 12 The late open artery hypothesis thus forms a 
solid theoretical basis in favour of late intervention in order 
to reperfuse occluded IRAs. However, late PCI on IRAs also 
has the potential for harm from procedure-related complica-
tions, distal embolization of atherothrombotic debris resulting 
in myocardial injury, and loss of recruitable collateral flow to 
other coronary territories.13-15
R A N D O m I z e D  T R I A l S  T e S T I N g  T h e  l A T e 
O p e N  A R T e R y  h y p O T h e S I S
Several randomized trials of small or modest sample sizes 
compared PCI versus medical therapy for total IRA occlusion 
late after MI. Although their results were not definitive, po-
tential improvements in left ventricular function and probably 
even clinical events suggested that late opening of occluded 
arteries after MI should be seriously considered.16-20 These 
studies were followed by the publication of OAT (Occluded 
Artery Trial) in 2006, which was the first large, randomized 
trial to test the late open artery hypothesis.21 This trial tested 
the hypothesis that routine PCI for total occlusion 3 to 28 
days after MI would reduce the composite endpoint of death, 
re-infarction, or NYHA class IV heart failure. Stable patients 
(n =2166) with an occluded infarct artery after MI (of whom 
almost 20% received fibrinolytic therapy for the index event) 
were randomized to optimal medical therapy and PCI with 
stenting or optimal medical therapy alone. Inclusion criteria 
included total occlusion of the infarct-related artery with 
TIMI grade 0 or 1 anterograde flow and left ventricular (LV) 
ejection fraction (LVEF) less than 50% or proximal occlusion 
of a major epicardial artery with large myocardial region at 
risk. Exclusion criteria included NYHA class III or IV heart 
failure, serum creatinine greater than 2.5 mg/dL, left main 
or 3-vessel disease, clinical instability, or severe inducible 
ischemia on stress testing if the infarct zone was not akinetic 
or dyskinetic. The 4-year combined end point was 17.2% in 
the PCI group and 15.6% in the medical therapy group (haz-
ard ratio-HR 1.16, 95% confidence intervals-CI 0.92 to 1.45, 
p = 0.2). Re-infarction rates tended to be higher in the PCI 
group, which may have attenuated any benefit in LV remodel-
ling. There was no interaction between treatment effect and 
any subgroup variable. It should be noted that even in the 
absence of significant effects on hard end-points, the OAT 
study showed that patients treated with PCI were significantly 
less likely to have angina at 4, 12, and 24 months, while that 
difference disappeared at the third year of follow up.
The Total Occlusion Study of Canada 2 (TOSCA-2) was 
a substudy of OAT which included 332 patients who were 
submitted to repeated coronary and LV angiography one 
year after randomization.22 Patients in the PCI group had the 
IRA patent in 83% of cases while this was true for only 25% 
of the medically treated patients. Despite this difference no 
significant benefit of the PCI strategy was found concerning 
LV function, in concert with the OAT results.
These results have challenged the late open artery hy-
pothesis and its clinical implications. Because of the findings 
of the OAT trial a new recommendation was included in the 
latest 2007 focused update23 of the ACC/AHA/SCAI 2005 
PCI guidelines: PCI of a totally occluded infarct artery greater 
than 24 hours after STEMI is not recommended (Class III) 
in asymptomatic patients with 1- or 2-vessel disease if they 
are hemodynamically and electrically stable and do not have 
evidence of severe ischemia (Level of Evidence: B).
Two recent meta-analyses testing the strategy of late PCI 
to recanalize an IRA
The first meta-analysis by Ioannidis and Katritsis24 
included data from the small and medium sized studies pub-
lished before OAT (Table 1), as well as data from the OAT 
trial and its sub-study TOSCA-2. The 2617 patients included 
were examined for clinical outcomes including death, MI, 
death or MI and congestive heart failure (CHF), while for 
653 of them a change in LVEF could be determined. There 
were no statistically significant differences for any clinical 
outcome, with trends for an increase in MI (risk ratio 1.26, P 
= 0.19) and decrease in CHF (risk ratio 0.67, P = 0.19) in the 
PCI arm. The PCI arm showed a slight superiority in LVEF. 
The authors concluded that the open artery hypothesis does 
not seem to translate into clinically meaningful advantages 
and that benefits of late reperfusion do not justify the costs 
and high radiation times for both patients and physicians 
encountered with interventions for recanalization of totally 
occluded IRAs.
In the second and most recent meta-analysis by Abbate et 
al,25 studies were included if they compared PCI with medical 
management and randomized clinically stable patients >12 
hours and up to 60 days after acute MI. Studies included 
were finally the same as in the meta-analysis of Ioannidis and 
Katritsis, with the inclusion of four additional studies, TOPS,26 
ALKK,27 BRAVE-23 and SWISSI II28 (Table 2). The analysis 
comprised 3560 patients yielding significantly improved sur-
vival in the PCI group (odds ratio-OR: 0.49, 95% CI: 0.26 to 
0.94, p = 0.030). These benefits were associated with similarly 
favourable effects on cardiac remodelling, such as improved 
LVEF in the PCI group.
The results of these two meta-analyses initially seem 
contradictory, however one can find an explanation when the 
four additional trials included in the second meta-analysis are 
closely examined. Their inclusion criteria were not adapted 
24
HOSPITAL CHRONICLES 4(1), 2009
T
A
B
l
e
 1
.*
 R
an
do
m
iz
ed
 s
tu
di
es
 p
ub
lis
he
d 
be
fo
re
 th
e 
O
pe
n 
A
rt
er
y 
T
ri
al
 (
O
A
T
)2
1  t
es
ti
ng
 th
e 
la
te
 o
pe
n 
in
fa
rc
t a
rt
er
y 
hy
po
th
es
is
.
St
ud
y
(y
ea
r)
pa
ti
en
ts
 
nu
m
be
r 
(p
C
I/
m
e
D
)
In
cl
us
io
n 
 
cr
it
er
ia
l
A
D
 a
s 
 
IR
A
D
ay
s 
fr
om
  
m
I 
to
 p
C
I
To
ta
lly
 
oc
cl
ud
ed
  
IR
A
(T
Im
I 
0-
1)
St
en
t
Fo
llo
w
 u
p 
(m
on
th
s)
e
nd
-p
oi
nt
s
Fi
nd
in
gs
TO
M
II
S1
6
(1
99
4)
44 (2
5/
19
)
ST
EM
I  
≤6
 w
ee
ks
 o
ld
PC
I:4
0%
,
M
ED
:4
7%
11
±
9
(a
ll 
≤6
 w
ee
ks
)
10
0%
0%
4
Pr
im
ar
y: 
LV
EF
By
 in
te
nt
io
n 
to
 tr
ea
t n
o 
sig
ni
fic
an
t i
m
pr
ov
e-
m
en
t w
ith
 P
C
I.
Im
pr
ov
ed
 
LV
EF
 
wh
en
 
IR
A
 
pa
te
nt
 
(+
9.
4±
6.
2%
), 
ve
rs
us
 
wh
en
 
no
n 
pa
te
nt
 
(1
.6
±
8.
8%
).
Se
co
nd
ar
y: 
Pa
te
nc
y s
ta
tu
s 
of
 th
e 
IR
A
By
 in
te
nt
io
n 
to
 tr
ea
t: 
PC
I: 
40
%
, M
ED
: 1
9%
 
(p
=
0.
23
1)
.
W
he
n 
PC
I 
su
cc
es
sfu
l: 
PC
I: 
60
%
, 
M
ED
: 
19
%
 (p
=
0.
04
7)
.
H
or
ie
 e
t a
l17
(1
99
8)
83 (4
4/
39
)
Q
 
wa
ve
 
an
te
ro
-se
pt
al
 
M
I, 
ad
m
iss
io
n 
>
24
 h
ou
rs
 
fro
m
 sy
m
pt
om
 o
ns
et
10
0%
8±
10
(1
-2
1)
10
0%
0%
60
Pr
im
ar
y: 
D
ea
th
, n
on
 fa
ta
l 
M
I, 
C
H
F
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
of
 to
ta
l c
ar
di
ac
 e
ve
nt
s 
an
d 
sin
gl
e 
pa
ra
m
et
er
s o
f t
he
 co
m
po
sit
e 
en
d-
po
in
t. 
Se
co
nd
ar
y: 
A
t 6
 m
on
th
s: 
LV
EF
, L
V
 re
gi
on
al
 w
al
l 
m
ot
io
n,
 L
V
ED
V
 in
de
x 
an
d 
LV
ES
V
 in
de
x
A
t 6
 m
on
th
s: 
sim
ila
r L
V
EF
 a
nd
 L
V
 re
gi
on
al
 
wa
ll 
m
ot
io
n.
R
ed
uc
ed
 L
V
ED
V
 in
de
x 
an
d 
LV
ES
V
 in
de
x 
wi
th
 P
C
I.
TO
A
T1
8
(2
00
2)
66 (3
2/
34
)
A
nt
er
io
r 
M
I, 
LA
D
 p
ro
xi-
m
al
 o
cc
lu
sio
n 
at
 c
or
on
ar
y 
an
gi
og
ra
ph
y, 
cli
ni
ca
l 
sta
-
bi
lit
y
10
0%
26
±
18
(3
-4
2)
10
0%
10
0%
12
Pr
im
ar
y: 
LV
 E
SV
, L
V
 
ED
V
, L
V
 fu
nc
tio
n
LV
 E
SV
, L
V
 E
D
V
: s
ig
ni
fic
an
tly
 in
cr
ea
se
d 
in
 
th
e 
PC
I g
ro
up
. L
V
EF
: n
o 
di
ffe
re
nc
e
Se
co
nd
ar
y: 
D
ea
th
, n
on
 
fa
ta
l M
I, 
C
H
F,
 st
ro
ke
, 
re
va
sc
ul
ar
iza
tio
n.
Q
oL
 m
ea
su
re
s
42
%
 in
cr
ea
se
d 
ad
ve
rs
e 
ev
en
ts 
wi
th
 P
C
I.
Im
pr
ov
em
en
t o
f Q
oL
 m
ea
su
re
s w
ith
 P
C
I
D
EC
O
PI
19
(2
00
4)
21
2
(1
09
/1
03
)
Q
-w
av
e 
M
I >
48
 h
ou
rs
 o
ld
, 
cli
ni
ca
lly
 st
ab
le
, n
o 
sp
on
ta
-
ne
ou
s 
or
 l
ow
 l
ev
el
 r
ec
ur
-
re
nt
 is
ch
em
ia
PC
I:2
7%
  
M
ED
:2
9%
2 
-1
5
10
0%
80
.4
%
34
Pr
im
ar
y: 
C
ar
di
ac
 d
ea
th
, 
no
n 
fa
ta
l M
I o
r V
T/
V
F
N
o 
di
ffe
re
nc
e 
(P
C
I: 
7.
3%
, 
M
ED
: 
8.
7%
, 
p=
0.
68
)
Se
co
nd
ar
y: 
C
ar
di
ac
 
de
at
h,
 n
on
 fa
ta
l M
I, 
V
T/
V
F 
or
 h
os
pi
ta
liz
at
io
n 
fo
r C
H
F.
LV
EF
 a
t 6
 m
on
th
s.
N
o 
di
ffe
re
nc
e 
fo
r 
th
e 
co
m
po
sit
e 
(P
C
I: 
10
.1
%
, M
ED
: 1
2.
6%
, p
=
0.
56
). 
H
ig
he
r (
5%
) 
LV
EF
 w
ith
 P
C
I. 
C
os
ts 
hi
gh
er
 w
ith
 P
C
I.
Po
st-
ho
c 
an
al
ys
is 
af
te
r 
an
gi
og
ra
ph
y 
at
 6
 
m
on
th
s: 
sig
ni
fic
an
tly
 lo
we
r a
ll 
ca
us
e 
an
d 
ca
r-
di
ov
as
cu
la
r 
m
or
ta
lit
y 
wh
en
 I
R
A
 w
as
 fo
un
d 
pa
te
nt
.
Si
lva
 e
t a
l20
(2
00
5)
30 (1
8/
12
)
A
nt
er
io
r M
Is
 ad
m
itt
ed
 0
.5
-
14
 d
ay
s 
af
te
r 
sy
m
pt
om
s, 
IR
A
 o
cc
lu
de
d,
 n
o 
m
od
er
-
at
e 
or
 s
ev
er
e 
isc
he
m
ia
 /v
i-
ab
ili
ty
 a
t t
he
 IR
A
 te
rr
ito
ry
10
0%
8±
3
10
0%
10
0%
6
Pr
im
ar
y: 
LV
 E
F 
an
d 
vo
lu
m
es
Im
pr
ov
em
en
t i
n 
LV
 E
F 
wi
th
 P
C
I, 
de
te
rio
ra
-
tio
n 
wi
th
 M
ED
. L
V
 vo
lu
m
es
 w
ith
ou
t s
ig
ni
fi-
ca
nt
 ch
an
ge
.
Se
co
nd
ar
y: 
A
dv
er
se
 
ca
rd
ia
c e
ve
nt
s
N
o 
sta
tis
tic
al
ly 
sig
ni
fic
an
t d
iff
er
en
ce
OPENING THE INFARCT-RELATING ARTERY
25
T
A
B
l
e
 2
.*
* 
R
an
do
m
iz
ed
 s
tu
di
es
 a
dd
ed
 in
 th
e 
m
et
a-
an
al
ys
is
 o
f A
bb
at
e 
et
 a
l.2
5  c
om
pa
re
d 
to
 th
e 
m
et
a-
an
al
ys
is
 o
f I
oa
nn
id
is
 a
nd
 K
at
ri
ts
is
.24
St
ud
y
(y
ea
r)
pa
ti
en
ts
 
nu
m
be
r 
(p
C
I/
m
ed
)
In
cl
us
io
n 
 
cr
it
er
ia
l
A
D
 a
s 
IR
A
Ti
m
e 
fr
om
 
m
I 
to
 p
C
I
To
ta
lly
 o
c-
cl
ud
ed
 I
R
A
 
(T
Im
I 
0-
1)
St
en
t
Fo
llo
w
 u
p 
(m
on
th
s)
e
nd
-p
oi
nt
s
Fi
nd
in
gs
TO
PS
26
(1
99
2)
87 (4
2/
45
)
Th
ro
m
bo
ly
se
d 
ST
E
M
I, 
ne
ga
tiv
e 
st
re
ss
 te
st
,
≥5
0%
 IR
A
  
st
en
os
is
PC
I:3
8%
 
M
E
D
:3
3%
4-
14
PC
I:1
0%
 
M
E
D
:1
3%
0%
12
Pr
im
ar
y:
 L
V
E
F 
ch
an
ge
 fr
om
 re
st
 
to
 e
xe
rc
ise
 a
ss
es
se
d 
by
 g
at
ed
 b
lo
od
-
po
ol
 sc
in
tig
ra
ph
y 
5-
7 
we
ek
s p
os
t M
IN
o 
di
ffe
re
nc
e 
be
tw
ee
n 
PC
I a
nd
 M
E
D
.
Se
co
nd
ar
y:
- A
t 1
2 
m
on
th
s: 
co
m
pa
ris
on
s o
f c
ar
-
di
ac
 e
ve
nt
 fr
ee
 su
rv
iv
al
, i
nf
ar
ct
io
n 
fr
ee
 su
rv
iv
al
, a
ng
in
a 
fr
ee
 su
rv
iv
al
.
- B
y 
5-
7 
we
ek
s: 
re
st
in
g 
LV
E
F 
an
d 
pe
ak
 e
xe
rc
ise
 h
ea
rt
 ra
te
A
t 1
2 
m
on
th
s w
or
st
 in
fa
rc
t f
re
e 
su
rv
iv
al
 
(8
8.
7%
 v
s 1
00
%
), 
bu
t s
lig
ht
ly
 b
et
te
r 
an
gi
na
 fr
ee
 su
rv
iv
al
 w
ith
 P
C
I.
N
o 
ot
he
r d
iff
er
en
ce
s.
A
LK
K
27
(2
00
3)
30
0 
(1
49
/1
51
)
ST
E
M
I 8
-4
2 
da
ys
 
ol
d,
 o
cc
lu
sio
n 
or
 
sig
ni
fic
an
t s
te
no
sis
 
of
 th
e 
IR
A
, c
lin
ic
al
 
st
ab
ili
ty
PC
I:3
5%
 
M
E
D
:3
7%
23
PC
I:2
9%
 
M
E
D
:2
8%
17
%
56
Pr
im
ar
y:
 A
t 1
 y
ea
r: 
D
ea
th
, r
e-
in
f-
ar
ct
io
n,
 re
va
sc
ul
ar
isa
tio
n,
 a
ng
in
a 
ne
ce
ss
ita
tin
g 
ho
sp
ita
liz
at
io
n
Bo
rd
er
lin
e 
re
du
ct
io
n 
of
 e
ve
nt
 fr
ee
 1
 y
ea
r 
su
rv
iv
al
 w
ith
 m
ed
ic
al
 th
er
ap
y 
(p
=
0.
06
6)
Se
co
nd
ar
y:
 S
ur
vi
va
l, 
re
-in
fa
rc
tio
n 
an
d 
re
va
sc
ul
ar
isa
tio
n 
lo
ng
-te
rm
 (5
6 
m
on
th
s)
A
t 5
6 
m
on
th
s: 
sig
ni
fic
an
t m
or
ta
lit
y 
re
du
ct
io
n 
wi
th
 P
C
I (
4 
vs
 1
1%
). 
A
lso
 
sig
ni
fic
an
t r
ed
uc
tio
n 
in
 re
-in
fa
rc
tio
n 
an
d 
re
va
sc
ul
ar
isa
tio
n.
BR
A
V
E
-2
3
(2
00
5)
36
5 
(1
82
/1
83
)
ST
E
M
I a
dm
itt
ed
 
12
-4
8 
ho
ur
s a
fte
r 
sy
m
pt
om
 o
ns
et
, n
o 
pr
ev
io
us
 th
ro
m
bo
ly
-
sis
, c
lin
ic
al
 st
ab
ili
ty
.
PC
I:3
7%
 
M
E
D
:3
8%
0.
5-
2
56
.6
%
 (o
nl
y 
27
%
 h
ad
 b
ot
h 
TI
M
I 0
 a
nd
 
R
en
tr
op
 0
)
87
.4
%
3
Pr
im
ar
y:
 L
V
 in
fa
rc
t s
iz
e 
as
se
ss
ed
 b
y 
SP
E
C
T 
wi
th
 T
c 
99
m
 se
st
am
ib
i 5
-1
0 
da
ys
 p
os
t r
an
do
m
iz
at
io
n
Si
gn
ifi
ca
nt
ly
 sm
al
le
r i
nf
ar
ct
 si
ze
 w
ith
 
PC
I
Se
co
nd
ar
y:
 D
ea
th
, M
I o
r s
tr
ok
e 
at
 
30
 d
ay
s
N
o 
sig
ni
fic
an
t d
iff
er
en
ce
 (a
rit
hm
et
ic
 
tr
en
d 
=
 3
3%
 re
la
tiv
e 
ris
k 
re
du
ct
io
n 
in
 
fa
vo
ur
 o
f P
C
I)
.
U
np
la
nn
ed
 P
C
I d
ur
in
g 
th
e 
30
 d
ay
 fo
l-
lo
w 
up
:
PC
I-
1.
1%
, M
E
D
-3
2.
8%
.
SW
IS
SI
 II
28
(2
00
7)
20
1
(9
6/
10
5)
ST
E
M
I o
r n
on
 
ST
E
M
I w
ith
in
 la
st
 
th
re
e 
m
on
th
s a
nd
 
sil
en
t i
sc
he
m
ia
 d
oc
-
um
en
te
d 
by
 st
re
ss
 
im
ag
in
g,
 1
 o
r 2
 V
D
 
su
ita
bl
e 
fo
r P
C
I
PC
I:6
0%
 
M
E
D
:6
1%
32
N
ot
 m
en
-
tio
ne
d
0%
12
0
Pr
im
ar
y:
 D
ea
th
, n
on
 fa
ta
l M
I, 
re
va
sc
ul
ar
isa
tio
n
Si
gn
ifi
ca
nt
ly
 re
du
ce
d 
ev
en
ts
 w
ith
 P
C
I
(h
az
ar
d 
ra
tio
 0
.3
3,
 9
5%
 C
I 0
.2
-0
.5
5,
 
p=
0.
00
1)
Se
co
nd
ar
y:
 E
xe
rc
ise
 in
du
ce
d 
isc
he
m
ia
, r
es
tin
g 
LV
E
F
Le
ss
 is
ch
em
ia
 in
 P
C
I p
at
ie
nt
s (
11
.6
%
 v
s 
28
.9
%
, p
=
0.
03
), 
LV
E
F 
pr
es
er
ve
d 
af
te
r 
PC
I b
ut
 d
ec
lin
e 
wi
th
 m
ed
ic
al
 th
er
ap
y.
*T
ab
le
 1
 A
bb
re
vi
at
io
ns
: C
H
F 
=
 c
on
ge
st
iv
e 
he
ar
t f
ai
lu
re
; I
R
A
 =
 in
fa
rc
t-
re
la
te
d 
ar
te
ry
; L
A
D
 =
 le
ft
 a
nt
er
io
r d
es
ce
nd
in
g 
(c
or
on
ar
y 
ar
te
ry
);
 L
V
 =
 le
ft
 v
en
tr
ic
-le
(-
ul
ar
);
 L
V
E
D
V
 =
 le
ft
 v
en
tr
ic
ul
ar
 
en
d-
di
as
to
lic
 v
ol
um
e;
 L
V
E
F 
=
 le
ft
 v
en
tr
ic
ul
ar
 e
je
ct
io
n 
fr
ac
tio
n;
 L
V
E
SV
 =
 le
ft
 v
en
tr
ic
ul
ar
 e
nd
-s
ys
to
lic
 v
ol
um
e;
 M
E
D
 =
 m
ed
ic
al
 th
er
ap
y;
 M
I 
=
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 P
C
I 
=
 p
er
cu
ta
ne
ou
s 
co
ro
na
ry
 in
te
rv
en
tio
n;
 Q
oL
 =
 q
ua
lit
y 
of
 li
fe
; S
T
E
M
I =
 S
T
-e
le
va
tio
n 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 V
D
 =
 v
es
se
l d
is
ea
se
**
Ta
bl
e 
2 
A
bb
re
vi
at
io
ns
: I
R
A
 =
 in
fa
rc
t-
re
la
te
d 
ar
te
ry
; L
A
D
 =
 le
ft
 a
nt
er
io
r d
es
ce
nd
in
g 
(c
or
on
ar
y 
ar
te
ry
);
 L
V
 =
 le
ft
 v
en
tr
ic
-le
(-
ul
ar
);
 L
V
E
F 
=
 le
ft
 v
en
tr
ic
ul
ar
 e
je
ct
io
n 
fr
ac
tio
n;
 M
E
D
 =
 m
ed
ic
al
 
th
er
ap
y;
 P
C
I =
 p
er
cu
ta
ne
ou
s c
or
on
ar
y 
in
te
rv
en
tio
n;
 S
T
E
M
I =
 S
T
-e
le
va
tio
n 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 V
D
 =
 v
es
se
l d
is
ea
se
26
HOSPITAL CHRONICLES 4(1), 2009
IRA>24 hours after an STEMI is not recommended (Class 
III, B – OAT contribution) in asymptomatic patients with 1- or 
2-vessel disease if they are hemodynamically and electrically 
stable and do not have evidence of severe ischemia.
These latest guidelines mix two groups of patients: those 
successfully submitted to fibrinolysis and late-comers who did 
not benefit from either fibrinolysis or primary PCI. In the first 
group there has been myocardial salvage and the latest ESC 
guidelines recommend routine coronary angiography and, if 
applicable, PCI early after effective thrombolysis (Class I, A) 
up to 24 hours after thrombolysis independent from angina 
and/or ischemia.2 The second group, late-comers who did 
not benefit from an early reperfusion (either thrombolysis 
or primary PCI), is quite heterogeneous. On the one hand 
and according to the guidelines, those who are clinically 
unstable should undoubtedly be treated with late PCI. On 
the other hand, those who are clinically stable can differ in 
many aspects: the time from symptom onset to presentation, 
the number of diseased coronary vessels, whether the IRA 
is occluded or spontaneously reperfused, the IRA territory, 
the presence and extent of silent or symptomatic ischemia, 
the presence of previously infracted myocardium, the LVEF 
and of course numerous other factors defining their general 
medical condition and their risk profile.
The OAT results,21 further supported by the meta-analy-
sis of Ioannidis and Katritsis,24 are by strict terms the best 
evidence to date testing the late open artery hypothesis. 
However, their discouraging results should not be interpreted 
as an argument against PCI to recanalize IRAs in all MI late-
comers. There is some debate on whether OAT patients are 
representative of real-life treatment scenarios. OAT excluded 
those patients with post-infarction angina and/or moderate to 
severe ischemia. However, one-third to two-thirds of patients 
have residual symptomatic or silent ischemia after AMI.29 
Recruitment in the OAT study was indeed difficult and inter-
rupted early; the explanation could be that many cardiologists 
believed PCI was beneficial for this group, leaving potentially 
less ideal candidates available for randomization. In addition, 
length of follow-up was limited, since less than one-half of the 
patients in OAT had a follow-up that reached 3 years. Of note, 
despite the lack of benefit concerning death, MI or NYHA 
class IV heart failure, there was significant relief from angina 
found with PCI during the first two years of follow up.
The most recent meta-analysis of Abbate et al.25 gave 
results in favor of PCI for a mixed population of late-comers 
after MI, but only after including data from trials not suitable 
to strictly test the late open artery hypothesis.
C O N C l U S I O N
The final message is that clinically stable late-comers 
after an acute MI are a diverse group, and decisions about 
to strictly test the late open artery hypothesis. The BRAVE- 2 
study, which comprised 365 patients, examined whether rou-
tine PCI of MI late-comers, in the time window of 12-48 hours 
after symptom onset, could provide benefit over initial medi-
cal therapy.3 It showed that infarct size can be significantly 
reduced with such a strategy, however only 56.6% of patients 
submitted to PCI were found with an occluded IRA (defined 
as having TIMI flow 0 or I) at the time of intervention. A trend 
towards a reduction of the composite of death, MI or stroke 
at 30 days was also found (relative risk reduction: 33%). The 
ALKK study included 300 clinically stable patients, 8-42 days 
after MI.27 The IRA was found occluded in less than one third 
of patients randomized to PCI or medical therapy, and PCI 
was related to a significant mortality reduction (4% versus 
11% with medical therapy), during long-term follow up (56 
months). Re-infarction and the need for revascularization were 
also reduced significantly. The SWISSI II study included 201 
patients, who had ST-elevation MI (STEMI) or non-STEMI 
within the last three months, silent ischemia documented by 
stress imaging and 1 or 2 vessel disease suitable for PCI.28 
Stents were not used and patients were followed for 10 years. 
Death, non fatal MI or revascularization were significantly re-
duced with PCI (HR: 0.33), as was exercise induced ischemia. 
TOPS was a smaller study (87 patients) published in the early 
90s.26 Patients were randomized to PCI or medical therapy if 
at 4-14 days after thrombolysis they had a negative stress test 
and an IRA with ≥50% stenosis. Less than 15% of patients 
had an occluded IRA. Infarct free survival was somehow 
worse with PCI at 1 year (88.7% vs 100%), but angina-free 
survival was better. In general, these four studies added to 
the meta-analysis of Abbate et al25 a large number of patients 
(n=953) with clinical scenarios more encouraging towards an 
interventional strategy. Their addition apparently led to an 
analysis with results in favour of PCI, in contrast to the study 
of Ioannidis and Katritsis 24 which included only studies closer 
to the late open artery hypothesis paradigm.
h O w  T O  D e A l  w I T h  T h e  I R A  O F  A 
l A T e - C O m e R  I N  C l I N I C A l  p R A C T I C e
According to the latest focused update of the ACC/AHA/
SCAI guidelines,23 PCI is recommended (Class I) after suc-
cessful fibrinolysis or in patients not undergoing primary 
reperfusion within the first 12 hours, when any of the following 
is true: objective evidence of recurrent MI (class I, C), pres-
ence of moderate or severe spontaneous or induced ischemia 
after MI (class I, B), cardiogenic shock or hemodynamic in-
stability (class I, B). Furthermore, it is reasonable to perform 
routine late PCI after an MI (class IIa, C) in patients with 
LVEF <0.40, heart failure, serious ventricular arrhythmias 
or even documented CHF only during the acute episode with 
subsequent LVEF>0.40. However, PCI of a totally occluded 
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late PCI on their IRAs should be individualized. The correct 
approach should not be to routinely recanalize any IRA, but 
rather to search for correct arguments before doing so, after 
thoroughly but swiftly analyzing any given patient’s clinical 
situation. For the moment the existing evidence seems still 
incomplete and current guidelines, although helpful, can not 
replace the physician’s judgment in many clinical scenarios 
of real practice.
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